Company
Business
Stem Cell Therapy
Organoid
CDMO Business
IR Resource Center
Kangstem Biotech strives to develop an innovative new drug for patients suffering from rare and incurable diseases.
MTN Interview_Bae Yo-han, Director of Clinical Development Division
12
2024.08
Dr. Yohan Bae, Head of Clinical Development at Kangstem Biotech, was recently interviewed on the MTN program.
Dr. Yohan Bae, Head of Clinical Development at Kangstem Biotech, was recently interviewed on the MTN program.
During the interview, he provided detailed insights into the company's business strategies, including the technology export of the atopic dermatitis treatment “Furestem-AD®Inj.” and advanced in regenerative medicine.
He also discussed the status of the Phase 1 clinical trial for the osteoarthritis treatment “OSCA” future plans such as the announcement of trial results, and participation in upcoming conferences.
Additionally, Dr. Bae outlined Kangstem Biotech's plans for the second half of the year.
<Highlight>
■ Atopic Dermatitis Treatment "Furestem-AD® Inj."
1) Over 600 patients have been followed for up to 5 years with no safety issues reported.
2) Long-term effectiveness is maintained after a single dose, with an EASI-50 achievement rate of 72% and an EASI-75 achievement rate of 54% at 12 months.
3) We are exploring technology export opportunities with multinational companies in the United States and China. Specifically, we are pursuing a pre-IND meeting with the FDA in collaboration with a U.S. pharmaceutical company.
4) We are preparing to enter the advanced regenerative medicine market both domestically and internationally.
■ Osteoarthritis Treatment "OSCA"
1) Phase 1 clinical trials are underway, with participants divided into low, medium, and high-dose groups based on stem cell dosage.
2) MRI data has been collected for the low and medium-dose groups. Notably, the medium-dose group demonstrated pain relief and structural improvements, such as cartilage regeneration, in all participants. These improvements in function and alongside structural enhancements, indicate disease recovery.
3) Several multinational companies have expressed interest and are closely monitoring the Phase 1 results. We plan to attend Bio Europe and other international conferences to promote technology export.
4) We are also preparing to conduct a Phase 2a clinical trial with 100 patients in Korea.
For more information, you can watch the video below.